Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NURSE.0000412932.50878.9c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Allele distribution and phenotypic resistance to ciprofloxacin and gentamicin among extended-spectrum β-lactamase-producing isolated from the urine, stool, animals, and environments of patients with presumptive urinary tract infection in Tanzania.
Front Antibiot
June 2023
Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Background: Additional antimicrobial resistance to extended-spectrum β-lactamase (ESBL)-producing exhausts treatment options. We investigated allele distribution and resistance to ciprofloxacin and gentamicin among ESBL-producing isolates from the urine, stool, animals, and environments of presumptive urinary tract infection (UTI) patients, in order to gain a crucial insight toward devising prevention and control measures and treatment guidelines.
Methods: Archived ESBL-producing isolates from the urine, stool, animals, and surrounding environments of presumptive UTI patients were retrieved.
A brief insight into species - a growing threat to public health.
Front Antibiot
December 2023
Department of Biochemistry & Microbiology, North South University, Dhaka, Bangladesh.
spp. are Gram-negative, non-spore forming, rod-shaped, facultative anaerobic bacteria from the family often found in soil, sewage, sludge, water, food, and the intestinal tracts of animals and humans. Several members of spp.
View Article and Find Full Text PDFPrevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producing in the Gulf Cooperation Council countries.
Front Antibiot
June 2023
Department of Microbiology and Immunology, Weill Cornell Medicine - Qatar, Education City, Qatar Foundation, Doha, Qatar.
Introduction: Among Gram-negative bacteria (GNB), (), such as () and (), are the most clinically relevant pathogens in healthcare settings. Infections secondary to these pathogens are widely common but multidrug resistance (MDR) in has become a significant challenge with increased morbidity, mortality, and cost of management. The escalating global prevalence of MDR in has led to limited treatment options, raising an urgent need for novel antimicrobial therapy(s) and detailed studies exploring underlying resistance mechanisms.
View Article and Find Full Text PDFEpidemiology of extended-spectrum beta-lactamase producing Enterobacteriaceae in Qatar: A 3-year hospital-based study.
Front Antibiot
September 2022
Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Background: The incidence of ESBL infections is exponentially increasing with variable prevalence among geographical areas and treatment settings. Identifying local prevalence rate and patient-related factors will help in earlier recognition and initiation of appropriate antibiotics treatment of patients with ESBL infections.
Methods: Retrospective analysis of all positive cultures for ESBL producing Enterobacteriaceae collected in Al-Khor hospital from January 2010 to December 2012.
Tolerability of Sodium-Glucose Co-transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Cureus
December 2024
Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, SAU.
Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an emerging treatment for type 2 diabetes mellitus (T2DM). The effect and tolerability of SGLT2 inhibitors in patients with T2DM, especially related risk factors and susceptible populations, are an area of ongoing research. Aim The aim of this study was to evaluate the tolerability of SGLT2 inhibitors, particularly the risk associated with urogenital infection, in patients with T2DM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!